Fu, Jennifer
Egeberg, Alexander http://orcid.org/0000-0001-8257-1816
Holmes, Susan http://orcid.org/0000-0001-8571-2653
Vano-Galvan, Sergio http://orcid.org/0000-0003-2773-7494
Steinhoff, Martin http://orcid.org/0000-0002-7090-2187
Edwards, Roger
Bonfanti, Gianluca
Nagra, Ranjit
Wolk, Robert
Tran, Helen http://orcid.org/0009-0007-6053-6703
Law, Ernest http://orcid.org/0000-0002-6111-8008
Clinical trials referenced in this document:
Documents that mention this clinical trial
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
https://doi.org/10.1007/s13555-024-01260-7
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Funding for this research was provided by:
Pfizer
Article History
Received: 27 June 2024
Accepted: 13 August 2024
First Online: 10 September 2024
Declarations
:
: Jennifer Fu has received consultation fees from Pfizer. Alexander Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, AbbVie, Janssen, and Boehringer Ingelheim and has received honoraria for work as a consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Galapagos NV, SUN Pharmaceuticals, Samsung Bioepis, Pfizer, Eli Lilly, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen. Susan Holmes is an investigator for Pfizer and has undertaken paid consultancy work for Pfizer. Sergio Vano-Galvan has received research funding and honoraria for work as a consultant and/or speaker from Pfizer and Eli Lilly. Martin Steinhoff has received honoraria or investigative or consultation fees from or was an investigator for AbbVie, Almirall, Avon, Algorithm, Allergan, Bayer Health, Baiersdorf, Bristol Myers Squibb, Celgene, Chugai, Ducray, Eli Lilly, Galderma, Genentech, GSK, Incyte, Janssen, Johnson & Johnson, Kiniksa, LEO Pharma, L’Oreal, Maruho, Menlo Therapeutics, Mitsubishi, Novartis, Pfizer, Pierre-Fabre, Qatar Pharma, Regeneron, Sanofi, Toray, Trevi, Vertex, and ZymoGenetics. Roger Edwards is an employee of Health Services Consulting Corporation and received consultancy fees from Pfizer in connection with this study. Gianluca Bonfanti is an employee of Engineering Ingegneria Informatica, which is a paid subcontractor to Health Services Consulting Corporation. Ranjit Nagra, Robert Wolk, Helen Tran, and Ernest Law are employees of, and hold stock or stock options in, Pfizer.
: The protocol was reviewed and approved by the institutional review boards or ethics committees of the participating institutions. The study was conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice, and Helsinki Declaration of 1964 and its later amendments. Written informed consent was obtained from each patient, patient’s parent, or patient’s legal representative to participate in the study.